Compounds > 5,8-dimethoxy-2-(2-hydroxyethyl)amino-3-hydroxy-1,2,3,4-tetrahydronaphthalene
Page last updated: 2024-12-07

5,8-dimethoxy-2-(2-hydroxyethyl)amino-3-hydroxy-1,2,3,4-tetrahydronaphthalene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,8-dimethoxy-2-(2-hydroxyethyl)amino-3-hydroxy-1,2,3,4-tetrahydronaphthalene: RN given refers to (trans)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID125151
MeSH IDM0082065

Synonyms (7)

Synonym
64831-69-2
(2s,3s)-3-(2-hydroxyethylamino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol
5,8-dimethoxy-2-(2-hydroxyethyl)amino-3-hydroxy-1,2,3,4-tetrahydronaphthalene
(trans)-1,2,3,4-tetrahydro-3-((2-hydroxyethyl)amino)-5,8-dimethoxy-2-naphthalenol
5,8-dimethoxy-trans-2-(2-hydroxyethyl)amino-3-hydroxy-1,2,3,4-tetrahydronaphthalene
3-[(2-hydroxyethyl)amino]-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol
DTXSID00983425

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" to rats and rabbits can be fitted to a two-compartment open pharmacokinetic model (previous communications)."( Correlations between the pharmacological effects and the pharmacokinetic behaviour of tetraminol.
Astroug, H; Mihailova, D; Prodanova, K, 1985)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (80.00)18.7374
1990's1 (20.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
propranolol
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.		1.9710naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
2-naphthylamine
2-Naphthylamine: A naphthalene derivative with carcinogenic action.. 2-naphthylamine : A naphthylamine carrying the amino group at position 2.		1.9710naphthylaminecarcinogenic agent
selegiline
Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.		1.9710selegiline;
terminal acetylenic compound		geroprotector
n-(3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-n-(3-oxo-3-phenyl-2-methylpropyl)piperazine
N-(3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)piperazine: structure in first source		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials